AMR diagnostic specialist Gradientech raise $4.6mGradientech closes a USD 4.6 million rights issue to progress QuickMIC diagnostic system for ultra-rapid antibiotics susceptibility testing (AST). more ➔
123rf.com/Iculig AgomAb Therapeutics bags €21m Series A financingAgomAb Therapeutics, a company resulting from a collaboration of argenx SE and growth factor experts from the University of Turin, has completed a €21m Series A financing. more ➔
Novartis acquires inflammasome blocker company IFM TreNovartis has aquired all outstanding capital stock and paid US$310m upfront to Boston-based IFM Tre Inc., which commercialises three inflammasome blockers designed to treat chronic inflammatory dise … more ➔
EMA recommends bluebird’s ?-thalassemia gene therapyThe European Medicines Agency has granted conditional approval for bluebird bio NV’s gene therapy Zynteglo (LentiGlobin BB305) to treat the rare disease transfusion-dependent ?-thalassemia at its … more ➔
Selvita to spin out cancer businessKrakow-based Selvita S.A. has announced it will spin out its oncology unit this year resulting in two public companies, a CRO and a cancer therapeutics developer. more ➔
123rf.com/guniita Polyneuron Pharma raise CHF22.5m in Series A financingThe CHF22.5m Series A financing round of the Swiss specialist for autoimmune diseases was led by Sofinnova Partners and New Enterprise Associates together with contributions of existing investors. more ➔
Genfit prices IPO at $135mFrench liver disorder specialist Genfit SA has announced the pricing of its Nasdaq IPO of ADS and European private placement. more ➔
Evotec partners with Mark Foundation for Cancer Research Evotec AG and The Mark Foundation for Cancer Research have inked a R&D collaboration aimed at developing novel immunooncological drugs more ➔
Hookipa Pharma files for US-$86m IPOUS-Austrian arenavirus-based cancer and infectious diseases specialist Hookipa has has filed a prospectus for an US$86M Nasdaq IPO. more ➔
New approach to treat eye cancerA research team from Germany and Mexico has successfully targeted uveal melanoma (UM), the most common type of eye cancer. more ➔
123rf.com/Iculig
123rf.com/guniita
